Aarey Drugs & Pharmaceuticals (BOM:524412) Total Receivables: ₹1,503 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524412 Aarey Drugs & Pharmaceuticals Ltd BOM:524412
60 GF Score
Price ₹78.39
GF Value ₹58.31
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Aarey Drugs & Pharmaceuticals Total Receivables?

Aarey Drugs & Pharmaceuticals BOM:524412 +1.19% 60 Total Receivables is ₹1,503 Mil as of Mar. 2026. GuruFocus rates BOM:524412 with a GF Score™ of 60/100 and a GF Value™ of ₹58.31 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Aarey Drugs & Pharmaceuticals's Total Receivables for the quarter that ended in Mar. 2026 was ₹1,503 Mil.

Aarey Drugs & Pharmaceuticals Total Receivables Related Terms

Aarey Drugs & Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Aarey Drugs & Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarey Drugs & Pharmaceuticals Total Receivables Chart

Aarey Drugs & Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,363.03 1,987.92 1,999.92 1,634.02 1,502.59

Aarey Drugs & Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,634.02 0.00 1,478.30 0.00 1,502.59
BOM:524412
60GF Score
Aarey Drugs & Pharmaceuticals Ltd BOM:524412
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarey Drugs & Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹1,503 Mil mean?
Aarey Drugs & Pharmaceuticals (BOM:524412) has a Total Receivables of ₹1,503 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Aarey Drugs & Pharmaceuticals and its competitors.
Is Aarey Drugs & Pharmaceuticals' Total Receivables too high?
Aarey Drugs & Pharmaceuticals' current Total Receivables is ₹1,503 Mil. Overall, Aarey Drugs & Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aarey Drugs & Pharmaceuticals' Total Receivables compare to ZTS?
Aarey Drugs & Pharmaceuticals' Total Receivables of ₹1,503 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Aarey Drugs & Pharmaceuticals and its competitors. Aarey Drugs & Pharmaceuticals's current Total Receivables is ₹1,503 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarey Drugs & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals (BOM:524412) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹58.31, compared to a current price of ₹78.39 — trading 34.4% above its estimated fair value. The current Total Receivables is ₹1,503 Mil. Aarey Drugs & Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Aarey Drugs & Pharmaceuticals (BOM:524412), the current Total Receivables is ₹1,503 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarey Drugs & Pharmaceuticals (BOM:524412) Overvalued in 2026?

Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals stock appears to be overvalued. The current stock price of ₹78.39 is trading 34.4% above its estimated GF Value™ of ₹58.31. GuruFocus considers Aarey Drugs & Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524412:

  • Total Receivables: ₹1,503 Mil
  • GF Value™: ₹58.31 vs. price of ₹78.39 (34.4% above fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the BOM:524412 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarey Drugs & Pharmaceuticals Business Description

Other Exchanges AAREYDRUGS:India
Address 340/348, Narshi Natha Street, 107, Sahakar Bhavan, Masjid Bunder, Mumbai, MH, IND, 400 009
Aarey Drugs & Pharmaceuticals Ltd is engaged in bulk drug manufacturing and offers products for industrial applications. The company manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals. It is also involved in the trading of industrial solvents and chemicals. The products offered by the company include N-Methyl urea, Dimethyl urea, Mefenamic acid, Metformin, Doxaphylline, and BMD among others. The company principally carries out its business operations in India.
60GF Score

Get the complete analysis for BOM:524412

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹78.39
Price
₹58.31
GF Value